OBJECTIVE: To assess varying levels of response to aripiprazole adjunctive to standard antidepressant therapy (ADT) and the predictive value of an early response for a sustained response. METHOD: This post hoc analysis of 3 similarly designed randomized, double-blind, placebo-controlled phase 3 studies investigated the efficacy and safety of adjunctive aripiprazole to standard ADT in patients with major depressive disorder (DSM-IV-TR criteria) who had a prior inadequate response to 1-3 ADTs (CN138-139 [September 2004-December 2006], CN138-163 [June 2004-April 2006], and CN138-165 [March 2005-April 2008]). Response levels were defined as percent decreases from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score after 6 weeks of treatment, with a ≤ 25% decrease for minimal, > 25 to < 50% decrease for partial, ≥ 50% to < 75% decrease for moderate, and ≥ 75% decrease for a robust response to treatment. RESULTS: More patients receiving adjunctive aripiprazole exhibited a partial (23.9% vs 17.9%, P = .017), moderate (23.1% vs 15.0%, P < .001), and robust response (14.3% vs 7.4%, P < .001) compared with adjunctive placebo. Adjunctive aripiprazole treatment compared with adjunctive placebo treatment was associated with a significantly greater proportion of patients achieving an early response (week 2, ≥ 50% reduction in MADRS total score, n = 110/539 vs n = 47/525, P < .001, number needed to treat = 9) and an endpoint response (relative risk = 1.7, 95% CI = 1.4-2.0, P < .001, number needed to treat = 7). A univariate logistic regression analysis revealed that an early response was a significant predictor of endpoint remission (P < .001). CONCLUSIONS:Aripiprazole augmentation was associated with a significantly greater proportion of patients achieving a partial, moderate, or robust response to treatment compared with ADT alone. Patients showing an early response (week 2) to augmentation maintained their response through endpoint, suggesting that clinicians may make clinically meaningful decisions early during treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00095823, NCT00095758, and NCT00105196.
RCT Entities:
OBJECTIVE: To assess varying levels of response to aripiprazole adjunctive to standard antidepressant therapy (ADT) and the predictive value of an early response for a sustained response. METHOD: This post hoc analysis of 3 similarly designed randomized, double-blind, placebo-controlled phase 3 studies investigated the efficacy and safety of adjunctive aripiprazole to standard ADT in patients with major depressive disorder (DSM-IV-TR criteria) who had a prior inadequate response to 1-3 ADTs (CN138-139 [September 2004-December 2006], CN138-163 [June 2004-April 2006], and CN138-165 [March 2005-April 2008]). Response levels were defined as percent decreases from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score after 6 weeks of treatment, with a ≤ 25% decrease for minimal, > 25 to < 50% decrease for partial, ≥ 50% to < 75% decrease for moderate, and ≥ 75% decrease for a robust response to treatment. RESULTS: More patients receiving adjunctive aripiprazole exhibited a partial (23.9% vs 17.9%, P = .017), moderate (23.1% vs 15.0%, P < .001), and robust response (14.3% vs 7.4%, P < .001) compared with adjunctive placebo. Adjunctive aripiprazole treatment compared with adjunctive placebo treatment was associated with a significantly greater proportion of patients achieving an early response (week 2, ≥ 50% reduction in MADRS total score, n = 110/539 vs n = 47/525, P < .001, number needed to treat = 9) and an endpoint response (relative risk = 1.7, 95% CI = 1.4-2.0, P < .001, number needed to treat = 7). A univariate logistic regression analysis revealed that an early response was a significant predictor of endpoint remission (P < .001). CONCLUSIONS:Aripiprazole augmentation was associated with a significantly greater proportion of patients achieving a partial, moderate, or robust response to treatment compared with ADT alone. Patients showing an early response (week 2) to augmentation maintained their response through endpoint, suggesting that clinicians may make clinically meaningful decisions early during treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00095823, NCT00095758, and NCT00105196.
Authors: David J Muzina; Jessie S Chambers; Trixia A Camacho; James M Eudicone; Robert A Forbes; Robert M Berman; Ross A Baker Journal: Am J Manag Care Date: 2011-12 Impact factor: 2.229
Authors: Mauricio Tohen; Michael Case; Madhukar H Trivedi; Michael E Thase; Scott J Burke; Todd M Durell Journal: J Clin Psychiatry Date: 2010-02-23 Impact factor: 4.384
Authors: David J Nutt; Jonathan R T Davidson; Alan J Gelenberg; Teruhiko Higuchi; Shigenobu Kanba; Oğuz Karamustafalioğlu; George I Papakostas; Kaoru Sakamoto; Takeshi Terao; Mingyuan Zhang Journal: J Clin Psychiatry Date: 2010 Impact factor: 4.384
Authors: Craig H Mallinckrodt; Joel Raskin; Madelaine M Wohlreich; John G Watkin; Michael J Detke Journal: BMC Psychiatry Date: 2004-09-08 Impact factor: 3.630
Authors: Gregory M Chandler; Dan V Iosifescu; Mark H Pollack; Steven D Targum; Maurizio Fava Journal: CNS Neurosci Ther Date: 2010-10 Impact factor: 5.243
Authors: Robert M Berman; Maurizio Fava; Michael E Thase; Madhukar H Trivedi; René Swanink; Robert D McQuade; William H Carson; David Adson; Leslie Taylor; James Hazel; Ronald N Marcus Journal: CNS Spectr Date: 2009-04 Impact factor: 3.790
Authors: J Craig Nelson; Michael E Thase; Madhukar H Trivedi; Maurizio Fava; Jian Han; Quynh Van Tran; Andrei Pikalov; Ying Qi; Berit X Carlson; Ronald N Marcus; Robert M Berman Journal: Prim Care Companion J Clin Psychiatry Date: 2009
Authors: Robert M Berman; Michael E Thase; Madhukar H Trivedi; James A Hazel; Sabrina Vogel Marler; Robert D McQuade; William Carson; Ross A Baker; Ronald N Marcus Journal: Neuropsychiatr Dis Treat Date: 2011-05-24 Impact factor: 2.570
Authors: David L Dunner; Kimberly K Laubmeier; George Manos; Robert A Forbes; Ross A Baker; Robert M Berman Journal: Prim Care Companion CNS Disord Date: 2012-11-22
Authors: J Craig Nelson; Zia Rahman; Kimberly K Laubmeier; James M Eudicone; Robert D McQuade; Robert M Berman; Ronald N Marcus; Ross A Baker; John J Sheehan Journal: CNS Spectr Date: 2014-03-18 Impact factor: 3.790